European Neuropsychopharmacology
Volume 21, Issue 5 , Pages 401-413 , May 2011

Modulation of sensorimotor gating in prepulse inhibition by conditional brain glycine transporter 1 deletion in mice

  • Philipp Singer

      Affiliations

    • Laboratory of Behavioural Neurobiology, Federal Institute of Technology Zurich, Schorenstrasse 16, CH-8603 Schwerzenbach, Switzerland
    • ,
  • Detlev Boison

      Affiliations

    • R.S. Dow Neurobiology Laboratories, Legacy Research, 1225 NE 2nd Ave, Portland OR 97232, United States
    • ,
  • Hanns Möhler

      Affiliations

    • Institute of Pharmacology and Toxicology, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland
    • Institute of Pharmaceutical Sciences, Collegium Helveticum, Semper-Sternwarte, Schmelzbergstrasse 25, CH-8092 Zurich, Switzerland
    • Federal Institute of Technology Zurich, Semper-Sternwarte, Schmelzbergstrasse 25, CH-8092 Zurich, Switzerland
    • ,
  • Joram Feldon

      Affiliations

    • Laboratory of Behavioural Neurobiology, Federal Institute of Technology Zurich, Schorenstrasse 16, CH-8603 Schwerzenbach, Switzerland
    • ,
  • Benjamin K. Yee

      Affiliations

    • Laboratory of Behavioural Neurobiology, Federal Institute of Technology Zurich, Schorenstrasse 16, CH-8603 Schwerzenbach, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 44 655 74 17; fax: +41 44 655 72 03.

Received 20 November 2009 ,Revised 21 June 2010 ,Accepted 23 June 2010.

References 

  1. Adams RH, Sato K, Shimada S, Tohyama M, Püschel AW, Betz H. Gene structure and glial expression of the glycine transporter GlyT1 in embryonic and adult rodents. J. Neurosci. 1995;15:2524–2532
  2. Aragón C, López-Corcuera B. Glycine transporters: crucial roles of pharmacological interest revealed by gene deletion. Trends Pharmacol. Sci. 2005;26:283–286
  3. Bast T, Zhang WN, Heidbreder C, Feldon J. Hyperactivity and disruption of prepulse inhibition induced by N-methyl-D-aspartate stimulation of the ventral hippocampus and the effects of pretreatment with haloperidol and clozapine. Neuroscience. 2001;103:325–335
  4. Behrens MM, Ali SS, Dao DN, Lucero J, Shekhtman G, Quick KL, et al. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science. 2007;318:1645–1647
  5. Berger AJ, Dieudonne S, Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J. Neurophysiol. 1998;80:3336–3340
  6. Bergeron R, Meyer TM, Coyle JT, Greene RW. Modulation of N-methyl-D-aspartate receptor function by glycine transport. Proc. Natl. Acad. Sci. U. S. A. 1998;95:15730–15734
  7. Betz H, Gomeza J, Armsen W, Scholze P, Eulenburg V. Glycine transporters: essential regulators of synaptic transmission. Biochem. Soc. Trans. 2006;34:55–58
  8. Bolino F, Di Michele V, Di Cicco L, Manna V, Daneluzzo E, Casacchia M. Sensorimotor gating and habituation evoked by electrocutaneous stimulation in schizophrenia. Biol. Psychiatry. 1994;36:669–670
  9. Borowsky B, Hoffman BJ. Analysis of a gene encoding two glycine transporter variants reveals alternative promoter usage and a novel gene structure. J. Biol. Chem. 1998;273:29077–29085
  10. Boulay D, Pichat P, Dargazanli G, Estenne-Bouhtou G, Terranova JP, Rogacki N, et al. Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophrenia. Pharmacol. Biochem. Behav. 2008;91:47–58
  11. Braff DL, Stone C, Callaway E, Geyer MA, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology. 1978;15:339–343
  12. Braff DL, Grillon C, Geyer MA. Gating and habituation of the startle reflex in schizophrenic patients. Arch. Gen. Psychiatry. 1992;49:206–215
  13. Braff DL, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology. 2001;156:234–258
  14. Breier A, Malhotra AK, Pinals DA, Weisenfeld NI, Pickar D. Association of ketamine-induced psychosis with focal activation of the prefrontal cortex in healthy volunteers. Am. J. Psychiatry. 1997;154:805–811
  15. Briata P, Di Blas E, Gulisano M, Mallamaci A, Iannone R, Boncinelli E, et al. EMX1 homeoprotein is expressed in cell nuclei of the developing cerebral cortex and in the axons of the olfactory sensory neurons. Mech. Dev. 1996;57:169–180
  16. Buckland G, Buckland J, Jamieson C, Ison JR. Inhibition of startle response to acoustic stimulation produced by visual prestimulation. J. Comp. Physiol. Psychol. 1969;67:493–496
  17. Cabib S, Puglisi-Allegra S, Ventura R. The contribution of comparative studies in inbred strains of mice to the understanding of the hyperactive phenotype. Behav. Brain. Res. 2002;130:103–109
  18. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry. 2006;39:10–14
  19. Chen L, Muhlhauser M, Yang CR. Glycine tranporter-1 blockade potentiates NMDA-mediated responses in rat prefrontal cortical neurons in vitro and in vivo. J. Neurophysiol. 2003;89:691–703
  20. Clements JD, Westbrook GL. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 1991;7:605–613
  21. Csomor PA, Yee BK, Vollenweider FX, Feldon J, Nicolet T, Quednow BB. On the influence of baseline startle reactivity on the indexation of prepulse inhibition. Behav. Neurosci. 2008;122:885–900
  22. Curras MC, Pallotta BS. Single-channel evidence for glycine and NMDA requirement in NMDA receptor activation. Brain. Res. 1996;740:27–40
  23. Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, et al. Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic. Neuropsychopharmacology. 2005;30:1963–1985
  24. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clin. Neuropharmacol. 2001;24:43–49
  25. Dingledine R, Kleckner NW, McBain CJ. The glycine coagonist site of the NMDA receptor. Adv. Exp. Med. Biol. 1990;268:17–26
  26. Fatemi SH, Folsom TD. The neurodevelopmental hypothesis of schizophrenia, revisited. Schizophr. Bull. 2009;35:528–548
  27. Fejgin K, Pålsson E, Wass C, Finnerty N, Lowry J, Klamer D. Prefrontal GABA(B) receptor activation attenuates phencyclidine-induced impairments of prepulse inhibition: involvement of nitric oxide. Neuropsychopharmacology. 2009;34:1673–1684
  28. Fendt M, Li L, Yeomans JS. Brain stem circuits mediating prepulse inhibition of the startle reflex. Psychopharmacology. 2001;156:216–224
  29. Gabernet L, Pauly-Evers M, Schwerdel C, Lentz M, Bluethmann H, Vogt K, et al. Enhancement of the NMDA receptor function by reduction of glycine transporter-1 expression. Neurosci. Lett. 2005;373:79–84
  30. Geyer MA, Krebs-Thomson K, Braff DL, Swerdlow NR. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology. 2001;156:117–154
  31. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol. Psychiatry. 2002;7:1039–1053
  32. Graham FK. The more or less startling effects of weak prestimulation. Psychophysiology. 1975;12:238–248
  33. Grillon C, Ameli R, Charney DS, Krystal JH, Braff DL. Startle gating deficits occur across prepulse intensities in schizophrenic patients. Biol. Psychiatry. 1992;32:843–939
  34. Gulisano M, Broccoli V, Pardini C, Boncinelli E. Emx1 and Emx2 show different patterns of expression during proliferation and differentiation of the developing cerebral cortex in the mouse. Eur. J. Neurosci. 1996;8:1037–1050
  35. Hauser J, Rudolph U, Keist R, Möhler H, Feldon J, Yee BK. Hippocampal alpha5 subunit-containing GABAA receptors modulate the expression of prepulse inhibition. Mol. Psychiatry. 2005;10:201–207
  36. Heresco-Levy U, Bar G, Levin R, Ermilov M, Ebstein RP, Javitt DC. High glycine levels are associated with prepulse inhibition deficits in chronic schizophrenia patients. Schizophr. Res. 2007;91:14–21
  37. Hoffman HS, Searle JL. Acoustic variables in the modification of startle reaction in the rat. J. Comp. Physiol. Psychol. 1965;60:53–58
  38. Iwasato T, Datwani A, Wolf AM, Nishiyama H, Taguchi Y, Tonegawa S, et al. Cortex-restricted disruption of NMDAR1 impairs neuronal patterns in the barrel cortex. Nature. 2000;406:726–731
  39. Javitt DC. Glycine transport inhibitors and the treatment of schizophrenia. Biol. Psychiatry. 2008;63:6–8
  40. Javitt DC. Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. Curr. Opin. Drug. Discov. Dev. 2009;12:468–478
  41. Johnson JW, Ascher P. Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature. 1987;325:529–531
  42. Keck T, White JA. Glycinergic inhibition in the hippocampus. Rev. Neurosci. 2009;20:13–22
  43. Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, et al. The glycine transporter type 1 inhibitor N-[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior. J. Neurosci. 2003;23:7586–7591
  44. Koch M, Schnitzler HU. The acoustic startle response in rats–circuits mediating evocation, inhibition and potentiation. Behav. Brain Res. 1997;89:35–49
  45. Kodsi MH, Swerdlow NR. Prepulse inhibition in the rat is regulated by ventral and caudodorsal striato-pallidal circuitry. Behav. Neurosci. 1995;109:912–928
  46. Kretschmer BD, Koch M. Role of the strychnine-insensitive glycine binding site in the nucleus accumbens and anterodorsal striatum in sensorimotor gating: a behavioral and microdialysis study. Psychopharmacology. 1997;130:131–138
  47. Le Pen G, Kew J, Alberati D, Borroni E, Heitz MP, Moreau JL. Prepulse inhibition deficits of the startle reflex in neonatal ventral hippocampal-lesioned rats: reversal by glycine and a glycine transporter inhibitor. Biol. Psychiatry. 2003;54:1162–1170
  48. Lerma J, Zukin RS, Bennett MV. Glycine decreases desensitization of N-methyl-D-aspartate (NMDA) receptors expressed in Xenopus oocytes and is required for NMDA responses. Proc. Natl. Acad. Sci. U. S. A. 1990;87:2354–2358
  49. Lin Q, Peng Y, Willis WD. Glycine and GABAA antagonists reduce the inhibition of primate spinothalamic tract neurons produced by stimulation in periaqueductal gray. Brain Res. 1994;654:286–302
  50. Lipina T, Labrie V, Weiner I, Roder J. Modulators of the glycine site on NMDA receptors, D-serine and ALX 5407, display similar beneficial effects to clozapine in mouse models of schizophrenia. Psychopharmacology. 2005;179:54–67
  51. López-Corcuera B, Geerlings A, Aragón C. Glycine neurotransmitter transporters: an update. Mol. Membr. Biol. 2001;18:13–20
  52. Lynch JW. Molecular structure and function of the glycine receptor chloride channel. Physiol. Rev. 2004;84:1051–1095
  53. Martina M, Gorfinkel Y, Halman S, Lowe JA, Periyalwar P, Schmidt CJ, et al. Glycine transporter type 1 blockade changes NMDA receptor-mediated responses and LTP in hippocampal CA1 pyramidal cells by altering extracellular glycine levels. J. Physiol. 2004;557:489–500
  54. Mayer ML, Vyklicky L, Clements J. Regulation of NMDA receptor desensitization in mouse hippocampal neurons by glycine. Nature. 1989;338:425–427
  55. McCaughran J, Mahjubi E, Decena E, Hitzemann R. Genetics, haloperidol-induced catalepsy and haloperidol-induced changes in acoustic startle and prepulse inhibition. Psychopharmacology (Berl.). 1997;134:131–139
  56. Möhler H, Rudolph U, Boison D, Singer P, Feldon J, Yee BK. Regulation of cognition and symptoms of psychosis: focus on GABA(A) receptors and glycine transporter 1. Pharmacol. Biochem. Behav. 2008;90:58–64
  57. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, et al. Glycine binding primes NMDA receptor internalization. Nature. 2003;422:302–307
  58. Olivier B, Leahy C, Mullen T, Paylor R, Groppi VE, Sarnyai Z, et al. The DBA/2J strain and prepulse inhibition of startle: a model system to test antipsychotics. Psychopharmacology. 2001;156:284–290
  59. Ouagazzal AM, Jenck F, Moreau JL. Drug-induced potentiation of prepulse inhibition of acoustic startle reflex in mice: a model for detecting antipsychotic activity?. Psychopharmacology (Berl.). 2001;156:273–283
  60. Parwani A, Duncan E, Bartlett E, Madonick S, Efferen TR, Rajan R, et al. Impaired prepulse inhibition of acoustic startle in schizophrenics. Biol. Psychiatry. 2000;47:662–669
  61. Patel N, Hitzemann B, Hitzemann R. Genetics, haloperidol, and the Fos response in the basal ganglia: a comparison of the C57BL/6J and DBA/2J inbred mouse strains. Neuropsychopharmacology. 1998;18:480–491
  62. Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, et al. Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas. Neuropharmacology. 2008;55:743–754
  63. Puglisi-Allegra S, Cabib S. Psychopharmacology of dopamine: the contribution of comparative studies in inbred strains of mice. Prog. Neurobiol. 1997;51:637–661
  64. Puglisi-Allegra S, Kempf E, Cabib S. Role of genotype in the adaptation of the brain dopamine system to stress. Neurosci. Biobehav. Rev. 1990;14:523–528
  65. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry. 2005;10:434–449
  66. Reijmers LG, Vanderheyden PM, Peeters BW. Changes in prepulse inhibition after local administration of NMDA receptor ligands in the core region of the rat nucleus accumbens. Eur. J. Pharmacol. 1995;272:131–138
  67. Schweizer C, Balsiger S, Bluethmann H, Mansuy IM, Fritschym J-M, Mohler H, et al. The α2 subunit of GABAA receptors is required for maintenance of receptors at mature synapses. Mol. Cell. Neurosci. 2003;24:442–450
  68. Singer P, Boison D, Möhler H, Feldon J, Yee BK. Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. Behav. Neurosci. 2007;121:815–825
  69. Singer P, Feldon J, Yee BK. Interference of glycine transporter 1: modulation of cognitive functions via activation of glycine-B site of the NMDA receptor. CNS Agents Med. Chem. 2007;7:259–268
  70. Singer P, Boison D, Möhler H, Feldon J, Yee BK. Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?. Behav. Neurosci. 2009;123:1012–1027
  71. Singer P, Feldon J, Yee BK. Are DBA/2 mice associated with schizophrenia-like endophenotypes? A behavioural contrast with C57BL/6 mice. Psychopharmacology. 2009;206:677–698
  72. Singer P, Yee BK, Feldon J, Iwasato T, Itohara S, Grampp T, et al. Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1. Neuroscience. 2009;161:635–654
  73. Smith KE, Borden LA, Hartig PR, Branchek T, Weinshank RL. Cloning and expression of a glycine transporter reveal colocalization with NMDA receptors. Neuron. 1992;8:927–935
  74. Swerdlow NR, Geyer MA. Clozapine and haloperidol in an animal model of sensorimotor gating deficits in schizophrenia. Pharmacol. Biochem. Behav. 1993;44:741–744
  75. Swerdlow NR, Weber M, Qu Y, Light GA, Braff DL. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl.). 2008;199:331–388
  76. Tsai G, Ralph-Williams RJ, Martina M, Bergeron R, Berger-Sweeney J, Dunham KS, et al. Gene knockout of glycine transporter 1: characterization of the behavioral phenotype. Proc. Natl. Acad. Sci. U. S. A. 2004;101:8485–8490
  77. Tsien JZ, Chen DF, Gerber D, Tom C, Mercer EH, Anderson DJ, et al. Subregion- and cell type-restricted gene knockout in mouse brain. Cell. 1996;87:1317–1326
  78. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr. Bull. 2007;33:69–94
  79. Waziri R, Baruah S. A hyperglycinergic rat model for the pathogenesis of schizophrenia: preliminary findings. Schizophr. Res. 1999;37:205–215
  80. Webb TI, Lynch JW. Molecular pharmacology of the glycine receptor chloride channel. Curr. Pharm. Des. 2007;13:2350–2367
  81. Yang SY, Hong CJ, Huang YH, Tsai SJ. The effects of glycine transporter I inhibitor, N-methylglycine (sarcosine), on ketamine-induced alterations in sensorimotor gating and regional brain c-Fos expression in rats. Neurosci. Lett. 2010;469:127–130
  82. Yee BK, Chang DL, Feldon J. The effects of dizocilpine and phencyclidine on prepulse inhibition of the acoustic startle reflex and on prepulse-elicited reactivity in C57BL6 mice. Neuropsychopharmacology. 2004;29:1865–1877
  83. Yee BK, Tilly C, Pietropaolo S, Feldon J. The expression of prepulse inhibition of the acoustic startle reflex as a function of three pulse stimulus intensities, three prepulse stimulus intensities, and three levels of startle responsiveness in C57BL6/J mice. Behav. Brain Res. 2005;163:265–276
  84. Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, et al. Disruption of glycine, transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J. Neurosci. 2006;26:3169–3181
  85. Yoshida M, Suda Y, Matsuo I, Miyamoto N, Takeda N, Kuratani S, et al. Emx1 and Emx2 functions in development of dorsal telencephalon. Development. 1997;124:101–111
  86. Zhang W, Pouzet B, Jongen-Rêlo AL, Weiner I, Feldon J. Disruption of prepulse inhibition following N-methyl-D-aspartate infusion into the ventral hippocampus is antagonized by clozapine but not by haloperidol: a possible model for the screening of atypical antipsychotics. Neuroreport. 1999;10:2533–2538
  87. Zhang WN, Bast T, Feldon J. Effects of hippocampal N-methyl-D-aspartate infusion on locomotor activity and prepulse inhibition: differences between the dorsal and ventral hippocampus. Behav. Neurosci. 2002;116:72–84
  88. Zhang LH, Gong N, Fei D, Xu L, Xu TL. Glycine uptake regulates hippocampal network activity via glycine receptor-mediated tonic inhibition. Neuropsychopharmacology. 2008;33:701–711

PII: S0924-977X(10)00141-0

doi: 10.1016/j.euroneuro.2010.06.014

European Neuropsychopharmacology
Volume 21, Issue 5 , Pages 401-413 , May 2011

Article Tools

* Image Usage & Resolution